PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
April 3, 2026Kidney MedicineOpen Access

Health Care Resource Utilization and Associated Costs Across Proteinuria and Declining Kidney Function in Patients With IgA Nephropathy: A Retrospective Study in Three European Countries

View Full Paper
Ask AI
Bookmark
Share

Authors

AAAntonio Ramírez de ArellanoGBGarth BaxterSDSonali Dasgupta

Discussion

Loading...

Member takes

Overview

Retrospective analysis reveals high healthcare costs associated with declining kidney function and proteinuria in IgAN patients across Europe, suggesting significant economic implications.

Key Points

  • This research aims to assess healthcare resource utilization and costs in IgA nephropathy patients with varying proteinuria levels and declining kidney function.
  • Retrospective analysis of anonymized TriNetX data from 2015 to 2023.
  • Included patients diagnosed with IgAN in the UK, Spain, and Germany between 2015-2022.
  • Evaluated costs and visit types (inpatient, outpatient, emergency) classified by CKD stage and proteinuria levels.
  • Increased inpatient (Spain 1.9‒2.5; UK 2.2‒11.0) and outpatient visits (Spain 13.2‒38.9; UK 5.3‒13.9) with higher CKD stages in Spain and UK; low outpatient visits in Germany (2.9‒4.3).
  • Average annual costs per patient in Spain escalate from €487 for CKD stage G1-G2 to €26,559 for stage G5; UK costs similarly increase from £432.95 to £36,253.80.

Cite This Study

Arellano et al. (2026) studied this question.

synapsesocial.com/papers/69cf5e5f5a333a821460cb46https://doi.org/10.1016/j.xkme.2026.101344
View Full Paper
Ask AI
Bookmark
Share